LAUSR

ABSTRACT Objectives: To assess the risk of adverse events (AEs) associated with brentuximab vedotin in lymphoma patients. Methods: Articles were retrieved from PubMed, Cochrane, and Clinicaltrials Databases to identify randomized controlled trials (RCTs) comparing brentuximab vedotin with non-brentuximab vedotin in lymphoma patients. Results: A total of 2225 patients from 4 RCTs were included. Compared with the non-brentuximab vedotin group, the brentuximab vedotin group significantly increased the risk of all-grade AEs (RR 1.05, 95% CI: 1.00–1.10), and high-grade AEs (risk ratio [RR] 1.27, 95% confidence intervals [CI]: 1.01–1.58). The brentuximab vedotin group significantly increased the risk of all-grade peripheral sensory neuropathy (RR 2.29, 95% CI: 1.23–4.26), pyrexia (RR 1.23, 95% CI: 1.05–1.44), nausea (RR 1.51, 95% CI: 1.05–2.18), vomiting (RR 1.54, 95% CI: 1.08–2.19), diarrhea (RR 1.69, 95% CI: 1.44–1.98), and alopecia (RR 1.18, 95% CI: 1.00–1.39), respectively. The brentuximab vedotin group significantly increased the risk of high-grade sensory neuropathy (RR 4.79, 95% CI: 1.46–15.75), neutropenia (RR 1.48, 95% CI: 1.01–2.18), nausea (RR 2.65, 95% CI: 1.37–5.12), vomiting (RR 2.2, 95% CI: 1.17–4.12), and diarrhea (RR 1.85, 95% CI: 1.21–2.85). Conclusion: Brentuximab vedotin increased the risk of certain AEs in lymphoma patients.